Pfizer antes up $345M to settle long-running EpiPen antitrust claims as Viatris case moves ahead

Pfizer antes up $345M to settle long-running EpiPen antitrust claims as Viatris case moves ahead
fkansteiner
Thu, 07/15/2021 – 21:18